A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma
Eugene J. Koay(The University of Texas MD Anderson Cancer Center), Jason B. Fleming(The University of Texas MD Anderson Cancer Center), Yeon‐Ju Lee(Korea Institute of Ocean Science and Technology), Mayrim V. Rios Perez(The University of Texas MD Anderson Cancer Center), John Lowengrub(University of California, Irvine), Matthew H. G. Katz(The University of Texas MD Anderson Cancer Center), Rachna T. Shroff(University of Arizona), Christopher H. Crane(Memorial Sloan Kettering Cancer Center), Jeffrey E. Lee(The University of Texas MD Anderson Cancer Center), Shun Yu(University of Pennsylvania), Vittorio Cristini(Houston Methodist), Robert A. Wolff(The University of Texas MD Anderson Cancer Center), Muayad F. Almahariq(Biolog Life Science Institute), Michael P. Kim(The University of Texas MD Anderson Cancer Center), Naveen Garg(The University of Texas MD Anderson Cancer Center), Mohamed Zaid(The University of Texas MD Anderson Cancer Center), Anirban Maitra(NYU Langone Health), Ya’an Kang(The University of Texas MD Anderson Cancer Center), Dalia Elganainy(The University of Texas MD Anderson Cancer Center), Milind Javle(The University of Texas MD Anderson Cancer Center), Peter C. Park(The University of Texas MD Anderson Cancer Center), Newsha Nikzad(The University of Texas MD Anderson Cancer Center), Deyali Chatterjee(The University of Texas MD Anderson Cancer Center), Cullen M. Taniguchi(The University of Texas MD Anderson Cancer Center), Priya Bhosale(The University of Texas MD Anderson Cancer Center), Prajnan Das(The University of Texas MD Anderson Cancer Center), Dali Li(East China Normal University), Huaming Yan(University of California, Irvine), Ahmed M. Amer(Norwegian University of Science and Technology), Eric P. Tamm(The University of Texas MD Anderson Cancer Center), Rong Ye(The University of Texas MD Anderson Cancer Center), Anil Chauhan(Hospital of the University of Pennsylvania), Huamin Wang(The University of Texas MD Anderson Cancer Center), F. Anthony San Lucas(The University of Texas MD Anderson Cancer Center), Mauro Ferrari(University of Washington), Kim A. Reiss(University of Pennsylvania), Gauri R. Varadhachary(The University of Texas MD Anderson Cancer Center), Brian P. Hobbs(Tellabs (Canada))
Cited by 111
Related Papers
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
|Science|2008|4k
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine
|Science|2017|1.8k
<i>DAXX</i> / <i>ATRX</i> , <i>MEN1</i> , and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors
|Science|2011|1.7k
Altered Telomeres in Tumors with <i>ATRX</i> and <i>DAXX</i> Mutations
|Science|2011|1.1k